openPR Logo
Press release

Multiple Sclerosis Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | TG Therapeutics (BRIUMVI/ ublituximab-xiiy), Immunic, ANOKION, Osmotica Pharma, Alkermes, Biogen, Merck Healthcare, Clene Nanomedicine, Atara Biotherapeutics

02-28-2024 02:47 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Multiple Sclerosis Market Forecasts by DelveInsight Signal

The Multiple Sclerosis (MS) market is experiencing significant evolution with the introduction of innovative disease-modifying therapies, advancements in precision medicine approaches, and increasing emphasis on personalized treatment strategies, promising improved management and outcomes for patients. Ongoing research efforts and the expanding understanding of the underlying mechanisms of Multiple Sclerosis are driving innovation and shaping the landscape, ushering in a new era of care for individuals affected by this complex neurological condition.

DelveInsight's "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Sclerosis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Multiple Sclerosis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Multiple Sclerosis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Multiple Sclerosis: An Overview
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, the body's own immune system produces cells, and proteins (antibodies) to attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.

The damaged myelin forms scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted. People with Multiple Sclerosis generally develop symptoms in their late 20s, experiencing visual and sensory disturbances, limb weakness, gait problems, and bladder and bowel syndromes. Initially, they may have partial recovery, but over time they develop progressive disability.

Multiple Sclerosis-affected individuals may experience a variety of symptoms, physically, emotionally, mentally, and psychologically. The severity and types of symptoms differ among individuals; thus, symptoms differ among different people.

With the continuous efforts in research and development, various companies are developing therapies, NeuroVax (Immune Response BioPharma), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), and many others are expected to enter the 7MM market by 2032.

Multiple Sclerosis Market Key Facts
• The market size of Multiple Sclerosis in the seven major markets was found to be USD 22,381 million in 2020.
• As per DelveInsight, the Multiple Sclerosis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases of Multiple Sclerosis in the 7MM and the launch of new therapies in the market.
• The total 7MM prevalent cases of Multiple Sclerosis in 2022 were approximately 1,275,800 cases. The cases are expected to increase by 2032.
• The prevalent cases of Multiple Sclerosis in the United States were found to be approximately 723,500 cases.
• Among EU-5 countries, Germany had the highest number of prevalent cases of Multiple Sclerosis, which were approximately 211,601 cases in 2021. As per DelveInsight's analysis, this will increase by 2032. On the other hand, the prevalent population of Multiple Sclerosis in Spain was found to be approximately 45,425 cases which as per DelveInsight's analysis was the lowest in EU-5.

Get a Detailed Overview of the Evolving Multiple Sclerosis Market Trends @
https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Multiple Sclerosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Multiple Sclerosis therapies in the market. It also provides a detailed assessment of the Multiple Sclerosis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Multiple Sclerosis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Multiple Sclerosis Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Multiple Sclerosis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Multiple Sclerosis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Multiple Sclerosis Epidemiology Segmented as -
• Total Prevalent Cases of Multiple Sclerosis
• Prevalence of Multiple Sclerosis Based on Age
• Prevalence of Multiple Sclerosis Based on Age
• Phenotype-specific prevalent cases of Multiple Sclerosis
• Extent of Disability (EDSS) in Multiple Sclerosis

Get Key Insights Into the Evolving Multiple Sclerosis Epidemiology Trends @
https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to be launched during the study period. The analysis covers the market share by Multiple Sclerosis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Multiple Sclerosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Multiple Sclerosis Market @
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Multiple Sclerosis Therapeutics Assessment
The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat Multiple Sclerosis. Several major pharma and biotech companies are developing therapies for Multiple sclerosis. Currently, TG Therapeutics is leading the therapeutics market with its Multiple sclerosis drug candidates in the most advanced stage of clinical development.

On Feb. 27, 2024, TG Therapeutics announced the issuance of three additional patents by the United States Patent and Trademark Office (USPTO) for BRIUMVI® (ublituximab-xiiy), the first and only anti-CD20 monoclonal antibody approved in the US for patients with relapsing forms of multiple sclerosis (RMS) that can be administered in a one-hour infusion following the starting dose.

Leading Companies in the Multiple Sclerosis Therapeutics Market Include
TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and many others.

Emerging and Marketed Multiple Sclerosis Therapies Covered in the Report Include
• Ublituximab: TG Therapeutics
• IMU-838: Immunic
• ATA188: Atara Biotherapeutics
• ANK-700: ANOKION
• NeuroVax: Immune Response BioPharma Inc.
• CNM-Au8: Clene Nanomedicine
• Tolebrutinib (SAR442168): Sanofi
• Evobrutinib/M2951: Merck Healthcare KGaA
• Ublituximab: TG Therapeutics, Inc.
• ALKS 8700: Alkermes/Biogen
• Arbaclofen (Arbaclofen ER): Osmotica Pharmaceutical
And Many More

Learn More About the Emerging Therapies and key Companies in the Multiple Sclerosis Therapeutics Market @
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Multiple Sclerosis Competitive Intelligence Analysis
4. Multiple Sclerosis Market Overview at a Glance
5. Multiple Sclerosis Background and Overview
6. Multiple Sclerosis Patient Journey
7. Multiple Sclerosis Epidemiology and Patient Population
8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple Sclerosis Unmet Needs
10. Key Endpoints of Multiple Sclerosis Treatment
11. Multiple Sclerosis Marketed Products
12. Multiple Sclerosis Emerging Therapies
13. Multiple Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Multiple Sclerosis Market Outlook (7 major markets)
16. Multiple Sclerosis Access and Reimbursement Overview
17. KOL Views on the Multiple Sclerosis Market.
18. Multiple Sclerosis Market Drivers
19. Multiple Sclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Multiple Sclerosis Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | TG Therapeutics (BRIUMVI/ ublituximab-xiiy), Immunic, ANOKION, Osmotica Pharma, Alkermes, Biogen, Merck Healthcare, Clene Nanomedicine, Atara Biotherapeutics here

News-ID: 3403816 • Views:

More Releases from DelveInsight Business Research LLP

Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report 2024 (Updated)
EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2024" report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage,
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Recurrent Glioblastoma Pipeline Report DelveInsight's Recurrent Glioblastoma

All 5 Releases


More Releases for Multiple

Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)
Multiple Sclerosis Therapeutics Market – Increasing prevalence of multiple scl …
Multiple Sclerosis Therapeutics Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Multiple Sclerosis Therapeutics Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor analysis. This comprehensive
Global Multiple Sclerosis Market Size, Global Multiple Sclerosis Market Share, G …
The Global Multiple Sclerosis Market Size is majorly driven by the factors such as rising number of consolidations between the market players for exploring the untapped market opportunity across the world. Request for Sample of This Research Report @ https://bit.ly/2Nh6b4d Top Key Player:- Hoffmann-La Roche Ltd. Bayer Healthcare AG Teva Pharmaceuticals GlaxoSmithKline AbbVie Inc. Sonafi Pasteur Pfizer Inc. Merck & Company Novartis AG AB Science Opexa Multiple Sclerosis (MS) is a disease in which the insulating covers of nerves and spinal cord are
Multiple Ion Beam Microscopes Market- Multiple Ion Beam Microscopes Have Huge Ap …
An ion beam is a kind of charged particle beam which consists of ions. With the advancement of nanotechnology new and advanced fabrication techniques are required which helps in production of functional features in much smaller scales. Advanced techniques are being used for applications in material science which uses image surfaces producing different features in a nanoscale. Gas field ion source technology has the capability of combining helium and neon
Smart Antenna Market Report 2018: Segmentation by Type (Switched Beam Smart Ante …
Global Smart Antenna market research report provides company profile for Cobham Antenna Systems(Suffolk, United Kingdom), Intel Corp.( Santa Clara, California, United States), Samsung Electronics CoLtd. ( Seoul, South Korea), ArrayComm LLC ( California, United States), Alcatel-Lucent International Holdings Inc.( Paris, France), Motorola Solutions Inc.( Illinois, the U.S.) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017,
Thermoseal Group Multiple Award Winners
For the second year in a row, Thermoseal Group is the winner of the coveted Glass and Glazing Industry’s G-Award for ‘Component Supplier of the Year’ as announced at the prestigious Gala Dinner held at the Hilton on Park Lane Hotel in London on Friday 18 November 2016. This was a great day for Thermoseal Group who were also announced winners at two other awards events held that day